Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Assessment of Drug–Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects

Ayalasomayajula, Surya and Pan , Wei and Han , Yi and Yang, Fan and Langenickel, Thomas Heiko and Pal, Parasar and Yao Zong , Yuan and Sunkara, Gangadhar (2017) Assessment of Drug–Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 42 (2). pp. 309-318. ISSN 21070180

Abstract

Background and Objective: LCZ696 (sacubitril/valsartan), a novel angiotensin receptor neprilysin inhibitor has been recently approved for the treatment of patients with heart failure (HF) and reduced ejection fraction. As several HF patients are likely to use statins as co-medications, the potential for a pharmacokinetic drug–drug interaction between atorvastatin and LCZ696 was evaluated. Methods: This was an open-label, three-period, single-sequence study in 28 healthy Chinese male subjects wherein LCZ696 200 mg was administered twice daily for 5 days in period 1. Following a washout period, atorvastatin 80 mg was administered once daily for 4 days (period 2) and subsequently co-administered with LCZ696 200 mg for 5 days (period 3). Serial plasma samples were collected to determine pharmacokinetic parameters of LCZ696 analytes (sacubitril, LBQ657, and valsartan) and atorvastatin and its metabolites. Results: Atorvastatin co-administration had no effect on the pharmacokinetics of LBQ657, while the AUCτ,ss and Cmax,ss of sacubitril increased by 30 and 19 %, respectively, and the corresponding values for valsartan decreased by 19 and 9 %, respectively. Co-administration with LCZ696 increased Cmax,ss of atorvastatin, o-hydroxyatorvastatin, and p-hydroxyatorvastatin by 74, 68, and 108 %, respectively, and the AUCτ,ss of corresponding analytes increased by 34, 22, and 26 %, respectively. Conclusions: While atorvastatin had no significant impact on the pharmacokinetics of LCZ696 analytes upon co-administration, the Cmax of atorvastatin and its metabolites increased twofold, with a marginal increase in AUC (<1.3-fold). Multiple-dose administration of LCZ696 200 mg twice daily and atorvastatin 80 mg once daily either alone or in combination was generally safe and well tolerated in healthy subjects.

Item Type: Article
Date Deposited: 25 Oct 2017 00:45
Last Modified: 25 Jan 2019 00:45
URI: https://oak.novartis.com/id/eprint/28658

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.